CoChat

Integration of Affinity Selection–Mass Spectrometry and Functional Cell-Based Assays to Rapidly Triage Druggable Target Space within the NF-κB Pathway

Open access
Kutilek, Victoria D., Andrews, Christine L., Richards, Matthew P., Xu, Zangwei, Sun, Tianxiao, Chen, Yiping, Hashke, Andrew, Smotrov, Nadya, Fernandez, Rafael, Nickbarg, Elliott B., Chamberlin, Chad, Sauvagnat, Berengere, Curran, Patrick J., Boinay, Ryan, Saradjian, Peter, Allen, Samantha J., Byrne, Noel, Elsen, Nathaniel L., Ford, Rachael E., Hall, Dawn L., Kornienko, Maria, Rickert, Keith W., Sharma, Sujata, Shipman, Jennifer M., Lumb, Kevin J., Coleman, Kevin, Dandliker, Peter J., Kariv, Ilona, Beutel, Bruce · 2016 · SLAS Discovery
Cited by 32

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

The primary objective of early drug discovery is to associate druggable target space with a desired phenotype. The inability to efficiently associate these often leads to failure early in the drug discovery process. In this proof-of-concept study, the most tractable starting points for drug discovery within the NF-κB pathway model system were identified by integrating affinity selection-mass spectrometry (AS-MS) with functional cellular assays. The AS-MS platform Automated Ligand Identification System (ALIS) was used to rapidly screen 15 NF-κB proteins in parallel against large-compound libraries. ALIS identified 382 target-selective compounds binding to 14 of the 15 proteins. Without any chemical optimization, 22 of the 382 target-selective compounds exhibited a cellular phenotype consistent with the respective target associated in ALIS. Further studies on structurally related compounds distinguished two chemical series that exhibited a preliminary structure-activity relationship and confirmed target-driven cellular activity to NF-κB1/p105 and TRAF5, respectively. These two series represent new drug discovery opportunities for chemical optimization. The results described herein demonstrate the power of combining ALIS with cell functional assays in a high-throughput, target-based approach to determine the most tractable drug discovery opportunities within a pathway.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/1087057116637353

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 32

Metadata

Authors
Kutilek, V. D., Andrews, C. L., Richards, M. P., Xu, Z., Sun, T., Chen, Y., Hashke, A., Smotrov, N., Fernandez, R., Nickbarg, E. B., Chamberlin, C., Sauvagnat, B., Curran, P. J., Boinay, R., Saradjian, P., Allen, S. J., Byrne, N., Elsen, N. L., Ford, R. E., Hall, D. L., Kornienko, M., Rickert, K. W., Sharma, S., Shipman, J. M., Lumb, K. J., Coleman, K., Dandliker, P. J., Kariv, I., & Beutel, B.
Venue
SLAS Discovery
Publisher
Elsevier BV
Published
2016-07
Volume
21
Issue
6
Pages
608-619
ISSN
2472-5552 (ISSN-L)
OpenAlex
W2295441452
Cited by
32
References
4
FWCI
2.98
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Integration of Affinity Selection–Mass Spectrometry and Functional Cell-Based Assays to Rapidly Triage Druggable Target Space within the NF-κB Pathway. https://app.cochat.ai/papers/10.1177/1087057116637353
The paper
Kutilek, V. D., Andrews, C. L., Richards, M. P., Xu, Z., Sun, T., Chen, Y., Hashke, A., Smotrov, N., Fernandez, R., Nickbarg, E. B., Chamberlin, C., Sauvagnat, B., Curran, P. J., Boinay, R., Saradjian, P., Allen, S. J., Byrne, N., Elsen, N. L., Ford, R. E., . . . Beutel, B. (2016). Integration of Affinity Selection–Mass Spectrometry and Functional Cell-Based Assays to Rapidly Triage Druggable Target Space within the NF-κB Pathway. SLAS Discovery. https://doi.org/10.1177/1087057116637353

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.